


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula I



in free or salt form, where

R¹ is a monovalent aromatic group having up to 10 carbon atoms; and

R² and R³ together with the nitrogen atom to which they are attached denote a heterocyclic group having up to 10 ring atoms and having 1 to 4 hetero atoms in the ring system.

2. (Previously Presented) A compound according to claim 1, in which

R¹ is phenyl substituted by one or two substituents selected from cyano, halogen, carboxy or C₁-C₄-haloalkoxy, and optionally by C₁-C₄-alkyl or C₁-C₄-alkoxy, or R¹ is phenyl substituted by C₁-C₄-alkoxy; and

R² and R³ together with the nitrogen atom to which they are attached denote a heterocyclic group having up to 6 ring atoms and one or two hetero atoms in the ring.

3. (Previously Presented) A compound according to claim 1, in which

R¹ is phenyl substituted by one or two substituents selected from cyano, halogen, carboxy or C₁-C₄-haloalkoxy meta to the indicated naphthyridine ring and optionally by C₁-C₄-alkyl or C₁-C₄-alkoxy ortho to the indicated naphthyridine ring, or R¹ is phenyl substituted by C₁-C₄-alkoxy meta to the indicated naphthyridine ring; and

R² and R³ together with the nitrogen atom to which they are attached denote a heterocycl group having up to 6 ring atoms and one or two nitrogen atoms, or one nitrogen atom and one oxygen atom, in the ring, optionally substituted by hydroxy, carboxy, 5-membered O-heterocyclcarbonyl, aminocarbonyl, C₁-C₄-alkoxycarbonyl, C₁-C₄-alkylsulfonyl or C₁-C₄-alkyl optionally substituted by hydroxy, cyano, carboxy or C₁-C₄-alkoxycarbonyl.

4. (Previously Presented) A compound according to claim 1 in which

Confirmation No.: 3784

R^1 is phenyl optionally substituted by one, two or three substituents selected from the group consisting of cyano, C_1 - C_8 -alkyl, C_1 - C_8 -alkylthio, $-SO-C_1-C_8$ -alkyl, and phenyl fused with a heterocyclic ring having 3 to 8 ring atoms of which up to 4 can be carbon atoms and up to 4 can be hetero atoms; and

R^2 and R^3 together with the nitrogen atom to which they are attached denote a heterocyclic group having up to 6 ring atoms and one or two hetero atoms in the ring optionally substituted by carboxy, carboxy- C_1 - C_8 -alkoxy or C_1 - C_8 -alkoxycarbonyl- C_1 - C_8 -alkoxy, said heterocyclic group also optionally being substituted by C_1 - C_8 -alkyl or C_1 - C_8 -alkoxy.

5. (Previously Presented) A compound according to claim 4, in which R^1 is phenyl optionally substituted by one, two or three substituents selected from the group consisting of cyano, C_1 - C_4 -alkyl, C_1 - C_4 -alkylthio, $-SO-C_1-C_4$ -alkyl, and phenyl fused with a heterocyclic ring having 5 or 6 ring atoms of which up to 4 can be carbon atoms and up to 2 can be hetero atoms; and
- R^2 and R^3 together with the nitrogen atom to which they are attached denote a heterocyclic group having up to 6 ring atoms and one or two nitrogen atoms in the ring optionally substituted by carboxy, carboxy- C_1 - C_4 -alkoxy or C_1 - C_4 -alkoxycarbonyl- C_1 - C_4 -alkoxy, said heterocyclic group also optionally being substituted by C_1 - C_4 -alkyl.


6. (Original) A compound according to claim 1, which is
 3-[6-(3-hydroxy-pyrrolidin-1-yl)-[1,7]naphthyridin-8-yl]-benzonitrile;
 3-[6-(4-(2-cyano-ethyl)-piperazin-1-yl)-[1,7]naphthyridin-8-yl]-benzonitrile;
 1-[8-(3-cyano-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylic acid, lithium salt; or
 3-(6-piperazin-1-yl-[1,7]naphthyridin-8-yl)-benzonitrile;
 1-[8-(3-fluoro-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylic acid ethyl ester;
 sodium 1-[8-(3-fluoro-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylate;
 1-[8-(5-fluoro-2-methoxy-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylic acid ethyl ester;
 or
 potassium 1-[8-(5-fluoro-2-methoxy-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylate.


7. (Original) A compound according to claim 1, wherein R^1 and $-NR^2R^3$ are as shown in the following table:

R^1	NR^2R^3
-------	-----------

<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1C(=O)N</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1CO</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1COCC</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1CCCO</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1CC(O)C2CCCC2</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1C(=O)C2CCCC2</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1CO</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1C(=O)N</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1C(=O)O</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1CN(C)C</chem>

<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCN(CC(=O)O)CC1</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CCN1CCN(CC(=O)OC2CCCO2)CC1</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCN(CC(=O)S(=O)(=O)C)CC1</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CC(C)NC(C)CC1</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCNCC1</chem>
<chem>c1ccc(C#N)cc1</chem>	<chem>CN1CCCC1C(=O)O</chem>
<chem>c1ccc(Cl)cc1</chem>	<chem>CN1CCCC1C(=O)OCC</chem>
<chem>Oc1ccc(Cl)cc1</chem>	<chem>CN1CCCC1C(=O)OCC</chem>
<chem>c1ccc(Oc2ccccc2C(=O)O)cc1</chem>	<chem>CN1CCCC1O</chem>
<chem>c1ccc(Cl)cc1</chem>	<chem>CN1CCCC1C(=O)O</chem>
<chem>c1ccc(Cl)cc1</chem>	<chem>CN1CCCC1C(=O)OC2CCCO2</chem>





8.-14. (Cancelled)

15. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1, optionally together with a pharmaceutically acceptable diluent or carrier.

16. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 6, optionally together with a pharmaceutically acceptable diluent or carrier.

17. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 7, optionally together with a pharmaceutically acceptable diluent or carrier.

18.-26. (Cancelled)